Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

DELFI-Tumor Fraction assay

Laboratory Developed Test
Related tests:


The DELFI-TF assay delivers a genome-wide measure of the proportion of cfDNA derived from a tumor and it is highly correlated with the mutant allele fraction (MAF) that is often used to evaluate treatment response and resistance to immunotherapies in advanced cancer patients. The fragmentome-based assay has numerous advantages as it requires very little plasma, has a low cost of processing, and is not confounded by clonal hematopoiesis or driver mutation switches.
Fragmentome-based assay